Steroids reduce COVID-19 deaths among seriously ill patients, UK study suggests


(ABC News) – As the world awaits a COVID-19 vaccine, researchers studying possible treatments have found a commonly used steroid called dexamethasone that might help save one-third of patients who end up on ventilators.

While another drug, remdesivir, has been shown to help people severely ill with COVID-19 recover more quickly, this is the first time any drug has been shown to significantly boost the survival rate of patients on ventilators.

“This is an exciting clinical trial — it is the first study of this magnitude that has shown a significant decrease in mortality,” said Dr. Todd Ellerin, chief of infection prevention at South Shore Health.

The study, conducted in the United Kingdom, included almost 6,500 patients from 175 hospitals. The results have not yet been vetted through the traditional peer-review process.

Researchers found that patients on mechanical ventilators who were given a low dose of the steroid were more likely to recover than those who received standard care.

Meanwhile, the drug also seemed to benefit patients who required oxygen assistance without mechanical ventilation, reducing deaths in this group by about 20%.

The drug did not seem to help patients with milder COVID-19 symptoms who were able to breathe on their own.

Dexamethasone is a low-cost, widely available anti-inflammatory drug that has been around for almost 65 years. The drug worked so well that an independent monitoring board recommended that this part of the study end early so the public could see the results.

There has previously been ongoing debate on the use of steroids, as some studies have shown poor outcomes.


“I am not saying dexamethasone is for everyone,” Ellerin added, “but right now we need to strongly consider it for patients who are severely or critically ill from COVID-19.”

Experts emphasized that people who are less sick may not benefit from dexamethasone, and implored the American public to adhere to preventative measures that include social distancing, mask-wearing and hand hygiene.

“The study suggests that people in the latter, most severe stages will benefit, not patients from earlier stages,” Schaffner added. “It won’t prevent them from moving into serious sickness, but once you are there, the drug can be given and you can possibly reduce your chances for mortality.”